Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study-Reference-Cited by-同舟云学术

Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study

Published:2010-01-07 Issue:2 Volume:91 Page:276-283
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Ohtake Shigeki,Miyawaki Shuichi,Kiyoi Hitoshi,Miyazaki Yasushi,Okumura Hirokazu,Matsuda Shin,Nagai Tadashi,Kishimoto Yuji,Okada Masaya,Takahashi Masatomo,Handa Hiroshi,Takeuchi Jin,Kageyama Shinichi,Asou Norio,Yagasaki Fumiharu,Maeda Yasuhiro,Ohnishi Kazunori,Naoe Tomoki,Ohno Ryuzo

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-009-0480-5.pdf

Reference16 articles.

1. Uzuka Y, Liong SK, Yamagata S. Treatment of adult acute non-lymphoblastic leukemia using intermittent combination chemotherapy with daunomycin, cytosine arabinoside, 6-mercaptopurine and prednisolone-DCMP two step therapy. Tohoku J Exp Med. 1976;118(Suppl):217–25.

2. Cooperative Study Group on Leukemia and Allied Diseases. DCMP two-step therapy for acute myelogenous leukemia in adults. Jpn J Clin Oncol. 1978;8:133–40.

3. Ohno R, Kato Y, Nagura E, Murase T, Okumura M, Yamada H, et al. Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length. J Clin Oncol. 1986;4:1740–7.

4. Ohno R, Kobayashi T, Tanimoto M, Hiraoka A, Imai K, Asou N, et al. Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group. Cancer. 1993;71:3888–95.

5. Kobayashi T, Miyawaki S, Tanimoto M, Kuriyama K, Murakami H, Yoshida M, et al. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. J Clin Oncol. 1996;14:204–13.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia;International Journal of Hematology;2022-10-19

2. New Therapeutic Strategies for Adult Acute Myeloid Leukemia;Cancers;2022-06-05

3. The effectiveness of three different 7 + 3 induction regimes in China: A retrospective analysis in adult patients with acute myeloid leukemia;Pakistan Journal of Medical Sciences;2020-12-08

4. Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study;International Journal of Hematology;2019-08-31

5. DIFFERENCES IN EX-VIVO CHEMOSENSITIVITY TO ANTHRACYCLINES IN FIRST LINE ACUTE MYELOID LEUKEMIA;Mediterranean Journal of Hematology and Infectious Diseases;2019-02-26